• Home
• About us
• Products
• Partnering
• Investors
• Media
• Contact us

• Print page
• Bookmark page
• Email us

Admission to the Official List

Not for release or distribution or publication in whole or part in or into the United States, Canada, Japan or Australia

18 July 2007, Chippenham, UK - Vectura Group plc (“the Company”) (LSE: VEC), the pulmonary product development Company focused on respiratory and neurological diseases, is pleased to announce today that admission to the Official List of the UKLA (the "Official List") 315,334,490 ordinary shares ("Ordinary Shares") has occurred ("Admission") and that trading in its Ordinary Shares will become effective from 8.00 a.m. today.

Dr Chris Blackwell, Chief Executive of Vectura, commented:

“Today’s move to the Main Market is an important stage of the Company’s evolution, and is evidence of the strong progress that we have made since we listed on AIM in 2004. We look forward to welcoming new investors into Vectura, and we believe that the Main Market will enable us to further continue our commitment in growing and developing the Company.”

The Prospectus dated 17 July 2007, published in connection with the Admission has been submitted to the UK Listing Authority ("UKLA") and copies are available for inspection at the UKLA's document viewing facility, which is situated at:

Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

Copies of the Prospectus are also available from the Company's registered office or from its website for a period of one month.

- Ends -

Enquiries:

About Vectura
Vectura is a pulmonary drug development company focused principally on the development of a range of inhaled therapies for the treatment of respiratory and neurological diseases. The respiratory market is forecast to achieve sales of $32 billion by 2011. Vectura develops products to treat respiratory diseases such asthma, COPD and cystic fibrosis. Vectura also develops products where optimised delivery via the lungs into the blood stream can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.

Vectura has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company also seeks to develop certain programmes further through development to optimise value at a later licensing stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis where this complements Vectura’s business strategy.

Vectura has development collaborations with a broad range of pharmaceutical companies including Boehringer Ingelheim, Novartis, and Chiesi. The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, GSK, Merck KGaA, UCB and Otsuka as well providing revenue streams, complementary products and critical mass.

For further information, please visit Vectura’s website at www.vectura.com

This press release contains “forward-looking statements,” including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura’s actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programs; failure to obtain patent protection for discoveries; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.